Table 1.
Baseline characteristic and clinical presentation of patients with SJIA
| ILD (n = 35) |
Non-ILD (n = 141) |
P value | |
|---|---|---|---|
| Median age at onset(y) | 5.8 (4.4–9.5) | 6.8 (4.7–9.6) | 0.864 |
| Sex, n (%) | |||
| Male | 17 (48.6) | 74 (52.5) | 0.679 |
| Female | 18 (51.4) | 67 (47.5) | |
| Median follow-up duration(y) | 4.6 (3.7–10.2) | 6.3 (4.1–9.5) | 0.859 |
| Hepatosplenomegaly, n (%) | 19 (54.3) | 52 (36.9) | 0.060 |
| Arthritis, n (%) | 30 (85.7) | 112 (79.4) | 0.399 |
| TMJ | 1 (2.9) | 3 (2.1) | 1.000 |
| Cervical spine | 10 (28.6) | 19 (13.5) | 0.031* |
| Shoulder | 11 (31.4) | 28 (19.9) | 0.140 |
| Elbow | 10 (28.6) | 32 (22.7) | 0.465 |
| Wrists | 16 (45.7) | 47 (33.3) | 0.171 |
| Hip | 14 (40.0) | 31 (22.0) | 0.029* |
| Knee | 22 (62.9) | 84 (59.6) | 0.722 |
| Ankle | 12 (34.3) | 62 (44.0) | 0.299 |
| Knuckle and toe joints | 8 (22.9) | 35 (24.8) | 0.809 |
| MAS, n (%) | 14 (40.0) | 33 (23.4) | 0.047* |
| One episode | 10 (28.6) | 29 (20.6) | 0.307 |
| ≥ 2 episodes | 4 (11.4) | 4 (2.8) | 0.083 |
| Median JADAS-27 score | 15.0 (11.0–18.13) | 13.2 (9.3–16.5) | 0.244 |
TMJ temporomandibular joint, MAS macrophage activation syndrome. *P < 0.05